Profile data is unavailable for this security.
About the company
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
- Revenue in USD (TTM)2.04m
- Net income in USD-104.28m
- Incorporated2014
- Employees113.00
- LocationFusion Pharmaceuticals Inc270 Longwood Rd. SHAMILTON L8P 0A6CanadaCAN
- Phone+1 (289) 799-0891
- Websitehttps://fusionpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.71bn | 246.00 | 13.01 | 3.32 | 10.56 | 2.77 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.71bn | 88.00 | -- | 4.05 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 1.75bn | 436.00 | -- | 1.91 | -- | 4.85 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Novocure Ltd | 525.66m | -192.74m | 1.77bn | 1.45k | -- | 4.93 | -- | 3.37 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Inhibrx Inc | 1.78m | -271.16m | 1.79bn | 166.00 | -- | 145.94 | -- | 1,005.39 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Ardelyx Inc | 159.11m | -65.81m | 1.82bn | 267.00 | -- | 12.05 | -- | 11.43 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Fusion Pharmaceuticals Inc | 2.04m | -104.28m | 1.83bn | 113.00 | -- | 7.54 | -- | 894.64 | -1.42 | -1.42 | 0.0279 | 2.85 | 0.0069 | -- | 45.84 | 18,053.10 | -35.33 | -35.45 | -37.76 | -38.55 | -- | -- | -5,111.57 | -7,206.24 | -- | -- | 0.1704 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
| Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.85bn | 112.00 | -- | 3.76 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.87bn | 383.00 | -- | 2.52 | -- | 63.72 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.88bn | 167.00 | 29.60 | 3.35 | 18.66 | 4.57 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 1.90bn | 61.00 | -- | 3.34 | -- | 3,523.44 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.96bn | 141.00 | -- | 4.31 | -- | 8,364.95 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 10.81m | 12.77% |
| Avidity Partners Management LPas of 31 Dec 2023 | 6.50m | 7.68% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.31m | 6.27% |
| Perceptive Advisors LLCas of 09 Jan 2024 | 4.74m | 5.59% |
| Canada Pension Plan Investment Boardas of 31 Dec 2023 | 3.12m | 3.68% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 1.09m | 1.28% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 1.01m | 1.19% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 779.20k | 0.92% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 744.47k | 0.88% |
| 1832 Asset Management LPas of 31 Dec 2023 | 734.32k | 0.87% |
